Core Viewpoint - The report outlines the performance and investment strategy of the Dongfang Alpha Health Industry Mixed Initiation Fund for the second quarter of 2025, emphasizing its focus on the health industry and innovative pharmaceuticals, while detailing its financial metrics and investment allocations [1][3][5]. Fund Overview - The fund is managed by Dongfang Alpha Fund Management Co., Ltd. and is designed as a mixed-type open-end fund with a total share of 10,671,548.05 at the end of the reporting period [1][6]. - The fund employs a combination of top-down and bottom-up investment strategies, focusing on fundamental analysis to select securities related to the health industry [2][3]. Investment Strategy - The fund's investment strategy includes 11 key aspects, such as qualitative and quantitative analysis of economic trends, risk assessment, and asset allocation among stocks, bonds, and cash [1][2]. - It aims to capture sub-industry rotation opportunities within the health sector, particularly focusing on innovative pharmaceuticals and related stocks [2][10]. Financial Performance - As of June 30, 2025, the net asset value (NAV) for the Dongfang Alpha Health Industry Mixed Initiation A class was 0.9499, with a net value growth rate of -5.01%, while the C class had an NAV of 0.9496 and a growth rate of -5.04% [10][11]. - The performance benchmark for the fund is composed of various indices, including the CSI Medical and Health Index and the Hang Seng Index, with a target return that reflects a diversified approach [4][11]. Investment Composition - The fund's asset allocation at the end of the reporting period included 89.58% in stocks and 5.86% in bonds, with a significant portion of investments made through the Hong Kong stock market [13][14]. - The fund's top holdings are primarily in the manufacturing sector, particularly in healthcare, which accounted for 44.24% of the fund's net asset value [13][14]. Market Trends - The report highlights a strong performance in the pharmaceutical sector, particularly in innovative drugs, which have seen significant growth due to overseas business development (BD) collaborations [9][10]. - The Chinese innovative drug market is projected to exceed 150 billion yuan in total revenue for 2025, with a year-on-year growth rate of over 30% [10][11]. Regulatory Compliance - The fund management adheres to the Securities Investment Fund Law of the People's Republic of China and maintains compliance with all relevant regulations, ensuring the protection of investors' interests [8][9].